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Background: Quality of life (QoL) in patients with acromegaly is reduced irrespective of 
disease state. The contributions of multifactorial determinants of QoL in several disease 
stages are presently not well known.
Objective: To systematically review predictors of QoL in acromegalic patients.
Methods: Main databases were systematically searched using predefined search terms 
for potentially relevant articles up to January 2017. Inclusion criteria included separate 
acromegaly cohort, non-hereditary acromegaly, QoL as study parameter with clearly 
described method of measurement and quantitative results, N ≥  10 patients, article 
in English and adult patients only. Data extraction was performed by two independent 
reviewers; studies were included using the PRISMA flow diagram.
Results: We identified 1,162 studies; 51 studies met the inclusion criteria: 31 cross-sec-
tional observational studies [mean AcroQoL score 62.7 (range 46.6–87.0, n = 1,597)], 
9 had a longitudinal component [mean baseline AcroQoL score 61.4 (range 54.3–69.0, 
n = 386)], and 15 were intervention studies [mean baseline AcroQoL score 58.6 (range 
52.2–75.3, n = 521)]. Disease-activity reflected by biochemical control measures yielded 
mixed, and therefore inconclusive results with respect to their effect on QoL. Addition 
of pegvisomant to somatostatin analogs and start of lanreotide autogel resulted in 
improvement in QoL. Data from intervention studies on other treatment modalities were 
too limited to draw conclusions on the effects of these modalities on QoL. Interestingly, 
higher BMI and greater degree of depression showed consistently negative associations 
with QoL. Hypopituitarism was not significantly correlated with QoL in acromegaly.
Conclusion: At present, there is insufficient published data to support that biochem-
ical control, or treatment of acromegaly in general, is associated with improved QoL. 
Studies with somatostatin receptor ligand treatment, i.e., particularly lanreotide autogel 
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iNTRODUCTiON
The World Health Organization recognizes three patient-related 
health outcome goals in chronic disease management: reducing 
mortality, reducing morbidity, and improving quality of life 
(QoL) (1). QoL is a multidimensional entity that represents the 
functional effect of an illness and its consequent therapy upon 
a patient, as perceived by the patient (2). The initial focus on 
reducing mortality and improving morbidity as well as normal-
izing biochemical target values, i.e., IGF-I and growth hormone 
(GH), in patients with acromegaly has yielded successful results 
(3–5). Nevertheless, QoL remains a major concern, since it often 
remains reduced despite long-term biochemical cure (6). In both 
patients with active or controlled acromegaly, QoL has been 
reported to be markedly decreased relative to the normal popu-
lation, with some improvement after treatment. Studies, usually 
cross-sectional designed because of the rarity of the disease, have 
been exploring disease-related and general factors (e.g., age, 
gender) that can affect QoL of patients with acromegaly. These 
studies included rather heterogeneous groups of patients with 
acromegaly (in terms of disease stages, extent of disease control, 
and treatment history) (7, 8). Literature reports conflicting results 
about factors that affect QoL. For example, a number of studies 
found no correlation between biochemical control of acromegaly 
and QoL (9–11), whereas others reported a significant correlation 
(12, 13). A more consistent finding during long-term follow-up 
of acromegaly patients is the high prevalence of joint complaints, 
fatigue, and (neuro)psychological problems. There is increasing 
evidence that in patients with acromegaly an initial period of 
GH excess can cause permanent complications, despite long-
term cure. This has been shown, e.g., with structural changes in 
macroscopic brain architecture, irreversible radiological joint 
abnormalities, and body composition (14–18). As QoL in the 
general sense is a multifactorial entity, it is plausible to assume 
that QoL in patients with acromegaly is also determined by 
several factors, which may differ depending on the phase of the 
disease. Factors that may be of importance during the untreated 
phase of the disease (i.e., active disease) are not necessarily of 
equal importance during the early treatment phase (i.e., transi-
tion from active to controlled disease) and the subsequent phase 
of acromegaly in chronic-treated situation (usually remission). 
It is important to acknowledge different study designs and the 
timing of the QoL measurement in relation to the disease phase, 
and lack of available data when analyzing factors associated with 
QoL in acromegaly. For example, interventional studies focus 
predominantly on active or treatment-naïve patients. A limited 
number of longitudinal observational studies have included 
patients with changing disease status. Long-term effects of 
treatment, such as post-radiation effects or hypopituitarism, are 
inherent to treated acromegaly and will have a more prominent 
role than in active acromegaly. Cohorts including patients with 
both active and controlled disease are therefore particularly het-
erogeneous, limiting direct comparison (see also Figure 1). Based 
on evidence based medicine, it is crucial to identify which factors 
are most influential on QoL during a certain phase of the disease 
in order to develop suitable interventions aimed at improving 
QoL. Therefore, the aim of this systematic literature study was to 
evaluate predictors of QoL in patients with acromegaly in several 
stages of their diseases and to identify potentially modifiable fac-
tors as targets for interventions.
MeTHODS
This systematic review aimed to adhere to the current PRISMA 
guidelines (19).
Data Sources and Search
Seven electronic databases were searched for potentially rel-
evant articles. PubMed, EMBASE, Web of Science, PsycINFO, 
Academic Search Premier, COCHRANE, and CENTRAL 
were searched using the keywords “Pituitary Neoplasms,” 
“Pituitary Neoplasm,” “Pituitary Tumors,” “Pituitary Tumor,” 
“Pituitary Tumours,” “Pituitary Tumour,” “Pituitary Adenomas,” 
“Pituitary Adenoma,” “Growth Hormone-Secreting Pituitary 
Adenoma,” “Growth Hormone-Secreting Adenomas,” 
“Acromegaly,” “Quality of Life,” “Life quality,” “qol,” “daily func-
tioning,” “daily routine,” health related QoL,” “well-being,” and 
“wellbeing.”
Study Selection
Articles were retrieved based on analysis of title and abstract 
whether they met the following six inclusion criteria: (1) separate 
acromegaly cohort, (2) non-hereditary acromegaly, (3) QoL as 
parameter, with clearly described method of measurement and 
quantitative results, (4) N ≥ 10 patients, (5) article in English, and 
(6) adult patients only.
and pegvisomant have shown improved QoL, but consensus on the correlation with 
biochemical control is missing. Longitudinal studies investigating predictors in treat-
ment-naive patients and their follow-up after therapeutic interventions are lacking but 
are urgently needed. Other factors, i.e., depression and obesity were identified from 
cross-sectional cohort studies as consistent factors associated with poor QoL. Perhaps 
treatment strategies of acromegaly patients should not only focus on normalizing bio-
chemical markers but emphasize improvement of QoL by alternative interventions such 
as psychosocial or weight lowering interventions.
Keywords: acromegaly, quality of life, systematic review, depression, biochemical control
TABLe 1 | Quality of life (QoL) quality assessment (max. 10 points).
item Scoring method
QoL primary outcome No = 0
Yes = 1
Group composition Heterogeneous: active/controlled = 0
Homogenous: active vs./or controlled = 1
Questionnaires Generic only = 0
Disease-specific = 0
Domain-specific = 0
Generic + disease-specific = 1
Generic + domain-specific = 1
Disease-specific + domain-specific = 1
Generic + disease-specific + domain-specific = 2
Validation questionnaires No = 0
Yes, general validation = 1
Yes, validated in cultural study population = 2
QoL domains assessed One domain BPS = 0
Two domains BPS = 1
Three domains BPS = 2
Bio-psycho-social Three domains BPS + other = 3
Discussion of clinical 
implication QoL scores
No = 0
Yes = 1
FiGURe 1 | interpretation of the setting of the studied predictors.
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Articles detailing cohorts detailing growth hormone defi-
ciency (GHD) after acromegaly were considered a separate entity 
and excluded from the analysis. Studies based on similar cohorts 
were separately included.
Data extraction and Risk of Bias 
Assessment
Screening of potentially suitable articles, as well as assessing eli-
gibility, was performed by two independent reviewers. Inclusion 
in the final systematic review was done upon mutual agreement.
Information about the study size, origin of the patients, out-
come, and potential conflicts of interest were extracted from each 
study.
Only factors that were described in more than one article 
were included for the systematic review part. Factors were 
scored having (1) no significant association with QoL, (2) a 
significant association with a subscale of the QoL-instrument 
(positive- or negative association), or (3) a significant asso-
ciation with the total QoL-instrument (positive- or negative 
association). Results were stratified into general factors, 
disease-specific factors, or interventions inherently linked to 
acromegaly. Consensus was determined as all studies unidirec-
tionally described.
Quality of the selected articles was assessed using the 
Newcastle-Ottawa Quality Assessment Scale (NOS) for cohort 
studies/case control studies (20). The maximum score for each 
article was 4 stars for the item “selection,” 2 stars for the item 
“comparability,” and 3 stars for either the item “outcome” or 
“exposure,” respectively.
A customized evaluation tool (see Table  1) was drafted by 
our research group and used to determine the quality of QoL 
assessment specifically, with a maximum of 10 points. This 
tool comprises biological, psychological, and social elements of 
a patients’ QoL and further differentiates between generic and 
disease-specific QoL, allowing for both a global QoL assessment 
and a specific design (e.g., AcroQoL).
ReSULTS
Search Results and Study Characteristics
The search yielded 1,162 articles, of which 1,074 were excluded 
based on the title and abstract. The 88 remaining studies were 
checked for the aforementioned inclusion criteria; 15 of these 
studies were excluded on the basis of no description of predic-
tors of QoL, and another 9 studies because the patients had been 
diagnosed with GHD after treatment for acromegaly. Fifty-one 
studies were ultimately included (see also Figure  2): 8 case–
control studies and 43 cohort studies. Naturally, for the case–
control studies, only the cohorts of patients with acromegaly 
TABLe 2 | Selected studies.
Reference Study type Country, region of 
origin cohort
N QoL 
Questionnaires
Anagnostis 
et al. (21)
Case–controla Greece, Thessaloniki 40 AcroQoL
Biermasz et al. 
(22)
Cohort, 
intervention
The Netherlands, 
Leiden
14 NHP
Biermasz et al. 
(23)
Case–controla The Netherlands, 
Leiden
118 AcroQoL, SF36, 
NHP, MFI-20, 
HADS
Biermasz et al. 
(24)
Cohort The Netherlands, 
Leiden
118 AcroQoL, SF36, 
NHP, MFI-20, 
HADS
Bonapart et al. 
(25)
Cohort, 
longitudinal
The Netherlands, 
Rotterdam
14 SF36
Bronstein et al. 
(26)
Cohort, 
longitudinal
Brazil, multicenter 
trial
119 AcroQoL
Cannavo et al. 
(27)
Case–controla Italy Messina 56 AcroQoL
Caron et al. 
(28)
Cohort, 
intervention
France, multicenter 
trial: 27 centers in 9 
countries
90 AcroQoL
Caron et al. 
(29)
Cohort, 
intervention
France, multicenter 
trial: 27 centers in 9 
countries
90 AcroQoL
Celik et al. (30) Cohort Turkey, Istanbul 57 AcroQoL
Celik and 
Kadioglu (31)
Cohort Turkey, Istanbul 57 AcroQoL
FiGURe 2 | Prisma flow diagram.
(Continued)
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were studied in this review. Thirty-one studies were classified 
as cross-sectional observational studies, 9 had an observational 
longitudinal component, and 15 studies were intervention stud-
ies. The selected studies, as well as abstracted data, are shown 
in Table 2.
Baseline AcroQol-Scores
Eighty percent of studies used the disease-specific measurement 
instrument AcroQoL (n = 41). Mean AcroQoL scores in cross-
sectional studies were 62.7 (range 46.6–87.0, n = 1597, maximum 
score =  100). Baseline mean AcroQoL scores in longitudinal 
studies were of 61.4 (range 54.3–69.0, n = 386), and 58.6 (range 
52.2–75.3, n =  521) in intervention studies. Given the hetero-
geneity of the individual studies, no formal conclusions can be 
drawn as to whether the means of the different study types are 
statistically different.
Quality Assessment
The quality assessment with regard to general quality (NOS) and 
specific QoL quality can be found in Table S1 in Supplementary 
Material. Five studies were classified as high quality studies 
(NOS ≥  8), 33 studies were classified as medium quality stud-
ies (NOS 6-7), and 13 studies were classified as low quality 
studies (NOS ≤  5). Quality of QoL assessment was high in 12 
studies (≥9 points), medium in 25 studies (6–8 points), and low 
in 14 studies (≤5 points).
Described Factors/interventions
Disease-specific factors that were identified from cross-sectional 
and longitudinal studies were biochemical control (n = 23), IGF1 
Reference Study type Country, region of 
origin cohort
N QoL 
Questionnaires
Chin et al. (32), Cohort, 
intervention
Korea, multicenter 
trial: 11 centers in 
Korea
58 AcroQoL
Dantas et al. 
(33)
Cohort Brazil, Brasilia 42 SF36
Fathalla et al. 
(34)
Cohort Canada, Toronto 20 SF36, PIT QOL
Fujio et al. (35) Cohort, 
intervention
Japan, Kagoshima 41 SF36
Geraedts et al. 
(36)
Cohort, 
longitudinal
Germany, Munich 80 AcroQoL, SF36
Ghigo et al. 
(37)
Cohort, 
intervention 
Italy, multicenter trial: 
50 centers in 13 
countries
113 AcroQoL
Hatipoglu et al. 
(38)
Case–
control, 
interventiona
Turkey, Istanbul 20 AcroQoL
Hatipoglu et al. 
(39)
Cohort Turkey, Istanbul 30 AcroQoL
Hua et al. (9) Cohort Taiwan, Taipei 52 AcroQoL
Karaca et al. 
(40)
Cohort, 
intervention
Turkey, Kayseri 22 AcroQoL
Kauppinen-
Makelin et al. 
(41)
Cohort Finland, multicenter 
trial: 5 centers in 
Finland
231 15D
Kepicoglu et al. 
(42)
Cohort Turkey, Istanbul 133 AcroQoL
Leon-Carrion 
et al. (43)
Case–controla Spain, multicenter 
trial: 4 centers in 
Spain
34 AcroQoL
Lombardi et al. 
(44)
Cohort, 
intervention
Italy, multicenter trial: 
24 centers in Italy
16 NHP
Madsen et al. 
(45)
Cohort, 
intervention
Denmark, Aarhus 51 EuroQoL
Mangupli et al. 
(46)
Cohort, 
intervention
Venezuela, Caracas 18 AcroQoL
Matta et al. (47) Cohort France, Toulouse 28 AcroQoL
Milian et al. (48) Cohort, 
intervention
Germany, Tuebingen 93 AcroQoL, SF36, 
QLS-H, SCL-90
Miller et al. (49) Cohort United Kingdom, 
Oxford
58 AcroQoL, SF36, 
AIMS2
Neggers et al. 
(50)
Cohort, 
intervention
The Netherlands, 
Rotterdam
30 AcroQoL
Paisley et al. 
(12)
Cohort, 
longidutinal
United Kingdom, 
Manchester
56 AcroQoL, 
EUroQoL, PGWB, 
SSS
Reference Study type Country, region of 
origin cohort
N QoL 
Questionnaires
Postma et al. 
(51)
Cohort The Netherlands, 
multicenter trial: 
2 centers in The 
Netherlands
108 AcroQoL, SF36, 
MFI-20, HADS
Psaras et al. 
(52)
Cohort Germany, Tuebingen 37 AcroQoL, SF36, 
SCL-90-R
Psaras et al. 
(53)
Cohort Germany, Tuebingen 55 AcroQoL, SF36
Raappana et al. 
(54)
Cohort Finland, Oulou 22 15D
Roerink et al. 
(55)
Case–controla The Netherlands, 
Nijmegen
73 AcroQoL, SF36
Rowles et al. 
(56)
Cohort United Kingdom, 
Manchester
80 AcroQoL, 
EuroQoL, PGWB, 
SSS
Rubeck et al. 
(57)
Cohort Denmark, Aarhus 63 EuroQoL
Sardella et al. 
(58)
Cohort, 
longitudinal
Italy, Pisa 23 AcroQoL
Schopohl et al. 
(59),
Cohort Germany, multicenter 
trial: 13 centers in 
Germany
17 AcroQoL
Siegel et al. 
(60)
Cohort Germany, Aachen 41 AcroQoL, SF36
T’Sjoen et al. 
(10)
Cohort Belgium, multicenter 
trial: 37 centers 
in Belgium and 
Luxembourg
291 AcroQoL
Trainer et al. 
(61)
Cohort, 
intervention
United Kingdom, 
multicenter trial: 29 
centers
77 AcroQoL, 
EuroQoL
Trepp et al. (13) Cohort Switzerland, Bern 33 AcroQoL
van der Klaauw 
et al. (62)
Cohort, 
longitudinal
The Netherlands, 
Leiden
82 AcroQoL, SF36, 
HADS, MFI-20
Vandeva et al. 
(63)
Cohort, 
longitudinal
Bulgaria, Sofia 212 AcroQoL
Varewijck et al. 
(64)
Cohort The Netherlands, 
Rotterdam
15 AcroQoL, SF36
Wassenaar 
et al. (65)
Cohort The Netherlands, 
Leiden
58 AcroQoL, SF36, 
MFI-20, HADS
Webb et al. (66) Case–
control, 
longitudinala
Spain, multicenter 
trial: 16 centers in 
Spain
106 AcroQoL, 
EuroQoL
Yoshida et al. 
(67)
Cohort Japan, Kobe 38 AcroQoL
aFor case–control studies, only the cohorts detailing patients with acromegaly were 
studied.
TABLe 2 | Continued TABLe 2 | Continued
(Continued)
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TABLe 3 | Factors influencing QoL in acromegaly from cross-sectional observational studies.
Reference General factors Disease-specific factors
Age Female 
gender
Depression education BMi Biochemical 
control
Hypopituitarism GH Disease 
duration
iGF1 Tumor size Remission 
duration
Followup 
duration
Anagnostis et al. (21) 0 −− −− 0 0 0 0a 0 0
Biermasz et al. (23) − 0 −− 0 + 0 0 − −
Biermasz et al. (24) −− + −−
Cannavo et al. (27) 0 −−
Celik et al. (30) 0
Celik and Kadioglu (31) −− ++ 0 0
Dantas et al. (33) +
Fathalla et al. (34) 0 0
Hatipoglu et al. (38) −− −−
Hatipoglu et al. (39) 0 0 0 0 0
Hua et al. (9) 0
Karaca et al. (40) 0
Kauppinen-Makelin et al. (41) −− 0 −− 0 0, −−a −− ++
Kepicoglu et al. (42) 0 0 −− ++ −− 0 0 ++
Leon-Carrion et al. (43) −− ++ ++
Mangupli et al. (46) 0 0
Matta et al. (47) +
Milian et al. (48) −− 0 0 0
Miller et al. (49) 0
Postma et al. (51) 0 −− 0
Psaras et al. (52) 0 0 − 0
Psaras et al. (53) 0 0 0 0 0 0
Raappana et al. (54) 0
Rowles et al. (56) 0 0 0 0
Siegel et al. (60) −−
T’Sjoen et al. (10) 0 −− −− 0 0
Trepp et al. (13) ++ −−
Vandeva et al. (63) −− −− 0
Varewijck et al. (64) −
Wassenaar et al. (65) +/− 0 0, 0a 0 0 0
Yoshida et al. (67) −− 0 −−
++ positive correlation with QoL, +positive correlation with a subscale of QoL only, −−negative correlation with QoL, −negative correlation with a subscale of QoL only, 0 no significant correlation with QoL.
aNadir growth hormone (GH).
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(n = 17), GH (n = 11), hypopituitarism (n = 10), disease dura-
tion (n = 8), tumor size (n = 5), duration of remission (n = 4), 
nadir GH (n = 3), change in IGF1 (n = 2), and follow-up dura-
tion (n =  2). General predictors that were identified were age 
(n = 16), gender (n = 14), depression scores (n = 7), education 
(n = 5), BMI (n = 2), and physical activity (n = 2). (Retrospective) 
Interventions identified from cross-sectional studies were a his-
tory of radiotherapy (n =  15), surgery (n =  8), current use of 
somatostatin analogs (n = 4), and application of any treatment of 
acromegaly (not otherwise specified) (n = 2).
Interventions identified from intervention trials (QoL meas-
ured in patients with acromegaly before and after intervention) 
were somatostatin analogs (n =  8), pegvisomant (n =  3), and 
pituitary surgery (n = 3).
Results indicating whether a factor was described to have a 
significant positive, significant negative, or no significant effect 
are denoted in Table 3 for general and disease-specific factors, 
and in Table 4 for applied interventions (therapies).
Results from Cross-sectional Studies 
irrespective of Disease Status
In heterogeneous cohorts with both active and controlled dis-
ease, general factors that had a negative effect on QoL in patients 
with acromegaly were higher depression scores (21, 23, 31, 38, 
42, 43) and higher BMI (10, 41) (see also Tables 3 and 4). The 
disease-specific factor hypopituitarism was described to have 
no significant effect (39, 41, 56, 65), while previous/ongoing 
treatments could not be associated with QoL in acromegaly [i.e., 
any treatment of acromegaly (not otherwise specified) (10, 21), 
surgery vs. somatostatin analogs (57, 65)] and physical activity 
(33). Other predictors were either not reported, or no consensus 
was reached on other predictors, such as the demographic 
factors age and gender, the biochemical parameters GH, IGF1, 
or biochemical control, and the duration of either disease or 
remission.
Results from Cross-sectional Studies 
Stratified for Disease Status
In cohorts with patients with active acromegaly only (six stud-
ies), the general factors depression scores (43), age and female 
gender (63), had a significant negative effect on QoL. The 
disease-specific factor GH level was described to be positively 
correlated with QoL (43) (see Table 5). Other predictors were 
either not reported, or no consensus was reached between 
the respective articles, such as IGF1, biochemical control, and 
disease duration.
In cohorts of patients with acromegaly in remission only (11 
studies), the general factor depression scores (23) was found 
to have a negative association with QoL. The disease-specific 
intervention previous radiotherapy (23, 24, 62, 65) had a nega-
tive effect on QoL subscales, whereas follow-up duration (23) 
had a significant negative effect on QoL subscales. No signifi-
cant association was found for hypopituitarism (23, 62, 65) and 
remission duration (62, 63, 65) (see Table 6). Other predictors 
were either not reported, or no consensus was reached between 
the respective articles, such as the demographic factors age and 
TABLe 5 | Factors influencing QoL in patients with active acromegaly (cross-sectional).
Reference General factors Disease-specific factors
Depression Age Female gender iGF1 GH Disease duration Biochemical control
Hua et al. (9) 0
Leon-Carrion et al. (43) −− ++ ++
Matta et al. (47) +
Sardella et al. (58) 0 −
Vandeva et al. (63) −− −− 0
Varewijck et al. (64) −
++positive correlation with QoL, +positive correlation with a subscale of QoL only, −−negative correlation with QoL, −negative correlation with a subscale of QoL only, 0 no 
significant correlation with QoL.
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gender, the biochemical parameters GH, IGF1, or biochemi-
cal control, and the duration of either disease, remission, or 
follow-up.
Results from intervention Studies
Three intervention studies demonstrated a significant positive 
effect of lanreotide autogel treatment on QoL of naïve patients 
with acromegaly (28, 29, 44), two of those detail the same 
cohort. Pegvisomant addition to somatostatin receptor ligands 
also demonstrated to have significant positive effects, both in a 
cohort biochemically well-controlled by somatostatin analogs 
(50) and with suboptimal control (61) (see Table  7). A cohort 
in which patients using octreotide LAR for at least 3  months 
demonstrated no effect of the injection interval on QoL (22). No 
significant effect was found for the interventions pegvisomant vs. 
octreotide-LAR, a study in which treatment-naïve patients were 
randomized between either pegvisomant or octreotide-LAR 
with QoL as a secondary outcome (37), physical activity (38), a 
crossover trial with patients switching to either pasireotide- or 
octreotide LAR (26) and somatostatin analogs vs. somatostatin 
analogs plus pegvisomant, a study in which patients controlled on 
somatostatin analogs were randomized to either continuation of 
treatment or co-treatment with pegvisomant (45) (see Table 7). 
Other predictors were either not reported, or no consensus 
was reached between the respective articles, such as surgery or 
octreotide treatment.
Results from Longitudinal Studies
Longitudinal, defined as multiple-time point observational stud-
ies (nine studies), indicated that higher GH levels (25) as well as 
depression (36) had a significant negative impact on QoL during 
follow-up in patients with acromegaly. A reduction in IGF-1 sig-
nificantly improved QoL (12); hypopituitarism had no significant 
effect on QoL in follow-up (62, 66). No significant contribution to 
QoL was found for the factor IGF-1 (25), disease duration (58), 
duration of remission (62), and education (66) (see Table  8). 
Other predictors were either not reported, or no consensus was 
reached between the respective articles.
DiSCUSSiON
In the present systematic review that included 51 studies, we 
observed only a limited amount of randomized controlled trials 
with QoL as an endpoint. Only six randomized trials have been 
listed (37, 40, 44, 45, 50, 61), with only three of these investi-
gating baseline data of treatment-naïve patients (37, 40, 44). 
Several risk factors that have shown a significant effect on QoL in 
cross-sectional observational studies have not been studied in a 
longitudinal design, such as depression scores and BMI. Studies 
investigating treatment for either depression or BMI (with the 
exception of one study that studied physical therapy but not 
formally targeted BMI) are absent. There are very few studies 
that assess long-term QoL patients with acromegaly throughout 
different phases of the disease; current studies do not properly 
reflect the transition a patient makes from active to controlled 
disease.
The general factors depression scores and BMI had a signifi-
cant negative impact on QoL in a number of studies, in cohorts 
comprising both active and non-active patients. Intriguingly, 
the disease-specific factor hypopituitarism had no significant 
association with QoL in patients with acromegaly.
The association of depression scores with reduced QoL may be 
self-explanatory; previously, we have reported a marked superi-
ority of depression scores over other predictors of QoL (23, 36). 
Increased scores for psychopathology have been described to be 
prevalent in patients with acromegaly (16, 21, 62, 68). Whether 
this observation is caused by acromegaly per se or is the result of a 
chronic disease in general is not clear. The demonstrated consen-
sus on the significance of depression scores in QoL in patients with 
acromegaly provides further circumstantial evidence that paying 
attention to- and treatment of psychopathological comorbidities 
(by either psychological and/or pharmaceutical approaches) may 
provide added value to the chronic care of patients with acro-
megaly. However, no results on the effect of psychotherapy on 
QoL in patients with acromegaly have been published, whereas it 
has been a well-established intervention in several other chronic 
illnesses.
Higher BMI is considered to be associated with reduced 
QoL both in the general population and in those with chronic 
disease (69, 70); therefore, it is not surprising that there is a 
consensus on the significance of BMI as a factor in patients 
with acromegaly as well. Moreover, Turgut et al. reported that a 
polymorphism of the GH receptor leading to greater sensitivity 
(mirroring GH excess) correlated with increased BMI, suggest-
ing a role of GH in acquiring greater body mass (71), independ-
ent of acromegaly. Moreover, obesity is a common symptom in 
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acromegaly as GH excess changes one’s body composition even 
after biochemical control (72), making it a clinically relevant 
factor to be targeted in order to improve QoL in acromegaly. 
Up to now, only one study was performed aiming at weight 
reduction by physical activity, and this study failed to show 
an improvement in QoL (change in weight was not reported). 
Further research is needed to evaluate optimal weight reduction 
strategies in acromegaly and also take into account mobility 
issues related to arthropathy.
Many comorbidities, such as diabetes mellitus, which are more 
prevalent in acromegaly, may also influence QoL in this popula-
tion. Most published studies have too small numbers to evaluate 
these parameters.
Many studies have however corrected for the effect of 
hypopituitarism next to demographic variables without tak-
ing into account its individual effect. The observation that 
hypopituitarism was not associated with QoL in patients with 
acromegaly may therefore be biased, because hypopituitarism 
per se is well-known to be a relevant factor in studying health 
outcomes in other pituitary diseases. With that in mind, we 
excluded all studies that investigated cohorts with GHD after 
acromegaly. Second, treatment of other hormone deficien-
cies in GHD patients has been demonstrated to significantly 
ameliorate QoL which further substantiates our motivation to 
exclude this specific condition from the present study (73–76). 
Moreover, the degree of hypopituitarism may play an important 
role in its association with QoL. Fathalla et al. described that 
pan-hypopituitarism had a significant negative effect on QoL 
(34), however, as this was the only study that investigated the 
role of pan-hypopituitarism it was not included in the final 
table.
Remarkably, no consensus on the role of biochemical variables 
has been reached. GH was shown in one study to be positively 
associated with QoL in active acromegaly, whereas this asso-
ciation was disputed in other cross-sectional cohorts. Although 
normalization of GH and IGF-I levels are obviously an important 
goal for treatment of acromegaly, our results strongly suggests 
that QoL in acromegaly is a different entity in addition biochemi-
cal control per se and may warrant clinical attention transcending 
current criteria for remission.
Although it seems likely that biomedical treatment of acro-
megaly would improve its symptoms, including an improvement 
of QoL, convincing evidence for this is as yet missing. The 
interventions of treatment with pegvisomant and somatostatin 
receptor ligands, in particular lanreotide autogel (from cross-
sectional studies) reported a significant positive impact on QoL, 
while general treatment of acromegaly (not otherwise specified) 
and the comparison of surgery to somatostatin analogs were not 
reported to be significantly associated with QoL from available 
cross-sectional data. Obviously, it should be expected that treat-
ments of a similar class as lanreotide autogel would ameliorate 
QoL in an equally similar fashion. Interestingly, the results on 
the effect of surgery, long-since the gold standard for cure of 
acromegaly, are conflicting. This effect, however, has not been 
investigated in longitudinal trials, rendering evidence on the 
benefit of surgery in QoL therefore inconclusive. Recent stud-
ies show a trend toward a relative positive effect of surgery on 
TABLe 7 | interventions influencing QoL in patients with acromegaly (intervention studies).
Reference Factor Study characteristics Therapy effect (i.e., QoL 
change after therapy)
Biermasz et al. (22) Octreotide LAR interval 
injections
Patients uncontrolled on octreotide LAR (n = 14) receive 8 weeks washout followed 
by 6-week interval injections during 36 weeks
0
Bronstein et al. (26) Crossover pasireotide 
LAR vs. octreotide LAR
Patients without biochemical control after 1 year of somatostatin analogs switched 
from either pasireotide LAR or octreotide LAR (follow-up 12 months after crossover)
0
Caron et al. (28) Lanreotide autogel Treatment-naïve patients (n = 90) with macroadenomas received lanreotide autogel 
during every 28 days for 48 weeks
++
Caron et al. (29) Lanreotide autogel Treatment-naïve patients (n = 90) with macroadenomas received lanreotide autogel 
during every 28 days for 48 weeks
++
Chin et al. (32) Octreotide-LAR Newly diagnosed patients (n = 58) were prescribed octreotide-LAR for 24 weeks +
Fujio et al. (35) Pituitary surgery Newly diagnosed patients (n = 41) who achieved biochemical control after surgery 
were included
+
Ghigo et al. (37) Pegvisomant vs. 
octreotide LAR
Medical-treatment and radiotherapy-naïve patients (n = 113), randomization between 
4 weeks pegvisomant or octreotide LAR, followed by 48 weeks octreotide
0
Hatipoglu et al. (38) Physical activity Mixed cohort of patients (n = 20) exercised 3 days a week for 3 months. NB 
response rate <10%
0
Karaca et al. (40) Octreotide-LAR Treatment-näive patients (n = 22) were randomized to either octreotide LAR or 
pituitary surgery (follow-up 12 months)
0
Pituitary surgery 0
Lombardi et al. (44) Lanreotide autogel Uncontrolled patients (n = 51) received autogel injections every 6–8 weeks (dose 
titration) for 48–52 weeks
++
Madsen et al. (45) Somatostatin analogs 
vs. somatostatin 
analogs + pegvisomant
Patients controlled on somatostatin analogs (n = 18) randomized to unchanged 
continuation of somatostatin analogs or cotreatment with pegvisomant during 
24 weeks
0
Mangupli et al. (46) Octreotide-LAR Retrospective observational study, patients (n = 28) on octreotide-LAR were followed 
for 4 years
++
Milian et al. (48) Pituitary surgery Patients selected for operative treatment (n = 93) were tested preoperatively and 
3–12 months after surgery. No information on additional medical treatment
++
Neggers et al. (50) Pegvisomant Placebo-controlled crossover study (n = 20): patients controlled on somatostatin 
analogs receive addition of pegvisomant during long-acting SA-treatment in controlled 
patients during 36 weeks (2 × 16 weeks, 4 weeks washout)
++
GH/change in IGF1 after 
pegvisomant addition
0
Trainer et al. (61) Pegvisomant Patients uncontrolled on octreotide-LAR (n = 27) randomized to pegvisomant 
monotherapy or addition of pegvisomant to octreotide-LAR
++
Pegvisomant + long-
acting octreotide
++
++positive correlation with QoL, +positive correlation with a subscale of QoL only, −− negative correlation with QoL, −negative correlation with a subscale of QoL only, 0 no 
significant correlation with QoL.
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QoL, this trend is not supported by cross-sectional studies which 
predominantly show no correlation between surgery and QoL. 
Intervention trials are the optimum study design for investigating 
treatment, further research in larger populations than the current 
three intervention studies should be conducted to verify whether 
surgery indeed has a beneficial effect on QoL as it obviously is 
the first line treatment to establisg remission and amelioration of 
acromegalic symptoms.
Therefore, large trials with sufficient follow-up data which spe-
cifically studies QoL (generic and disease-specific) as a primary 
long-term outcome for each of the most widely used treatment 
strategies, either medicinal or surgical, are urgently needed. In 
an era of treatment choices and increasing focus on the patient 
perspective knowledge of the effect of distinct treatment options 
and modalities on QoL from prospective studies is of paramount 
importance to enable individually tailored decisions based on 
evidence based medicine.
The relation between GH/IGF1 excess and QoL is complex due 
limitations inherent to our current understanding of acromegaly. 
First, the reflection of disease activity is not straightforward 
and many different parameters to reflect GH excess have been 
used, usually single time-point measurements rather than time-
weighted average GH activity that may not reflect tissue exposure. 
In addition, a direct comparison between naïve active patients 
and treated/cured patients is often lacking, both in prospective 
studies and in cross-sectional studies. Given the fluctuations in 
GH levels throughout the day, as well as individual differences in 
set point and sensitivity, it is uncertain whether decisive evidence 
11
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proving the role of GH levels in QoL will be found in future 
research (77, 78).
Considering QoL as a complex entity with at least three 
domains (biological, psychological, and social components) (79), 
there may be disparity between generic QoL scores and disease-
specific/domain-specific scores. Because of limited numbers and 
the use of many different questionnaires (n = 12), we could not 
evaluate results for all questionnaires. Limitations of this review 
include the small size of the studies with heterogeneous cohorts 
(mean N =  53.47, range 10–291) and the limited amount of 
longitudinal studies and intervention studies.
A difficulty in comparing studies of different designs (cross-
sectional observational vs. intervention vs. longitudinal stud-
ies) is exemplified by differences in baseline QoL, particularly 
with regard to the range in QoL between the studies. Assuming 
a large difference in effect size of individual factors, direct 
comparison between the respective studies limits quantitative 
analyses.
A remarkable limitation in interpreting the results on 
biochemical control is the timeframe after which biochemi-
cal control was achieved. Although we report the parameters 
studied in both active acromegaly and acromegaly in remission, 
the largest portion of the studies was conducted in heteroge-
neous cohorts, which includes a large variety of disease- and 
follow-up durations. Despite this being a good reflection of 
clinical practice-cohorts, it may be beneficial to study QoL in 
acromegaly over an extended period of time, from diagnosis to 
long-term follow-up.
In conclusion, this article provides a comprehensive overview 
of the available literature until January 2017 for associative fac-
tors and predictors of QoL in acromegaly. It provides systematic 
evidence for the significant role of depression scores and BMI, 
but does not provide further arguments to support the role of 
biochemical parameters such as hormonal normalization as 
well as hypopituitarism and the main therapeutic modalities 
for acromegaly. At present, only interventions with lanreotide 
autogel and pegvisomant have shown to consistently improve 
QoL, while the effect of other interventions is either unclear 
or not properly assessed prospectively. Future research should 
include prospective and longitudinal measurements of QoL and 
the patient perspective to be able to use QoL scores in clinical 
decision making. Finally, treatment of depressive symptoms and 
BMI-reducing strategies are promising targets for QoL improve-
ment strategies.
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